Document Detail


Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
MedLine Citation:
PMID:  23235770     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
Authors:
Khurum H Khan; Audrey Fenton; Eimer Murtagh; James Ja McAleer; Alison Clayton
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Tumori     Volume:  98     ISSN:  2038-2529     ISO Abbreviation:  Tumori     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-12-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0111356     Medline TA:  Tumori     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  139e-42e     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Collecting duct carcinoma presenting uncommon metastatic features.
Next Document:  Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esop...